Haloperidol Ratiopharm (Haloperidol)

Haloperidol Ratiopharm is indicated for the management of several psychiatric disorders where dopamine blockade is therapeutic. It may be prescribed as a short‑term option or as part of a longer maintenance regimen, depending on clinical response and tolerability.

• Schizophrenia, including maintenance therapy and acute exacerbations.
• Acute psychotic episodes associated with mood disorders or substance use.
• Tourette syndrome, particularly for reducing motor and vocal tics.
• Severe agitation or aggression in hospitalized patients.
• Manic episodes of bipolar disorder when rapid control of symptoms is required.
• Adjunctive treatment for patients with refractory psychosis who have not responded adequately to other antipsychotics.

Haloperidol Ratiopharm can produce a range of adverse effects that vary in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and constipation.
• Blurred vision or dizziness.
• Weight gain or changes in appetite.
• Restlessness or difficulty concentrating.
• Nausea or gastrointestinal upset.
• Insomnia or sleep disturbances.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements of the face or tongue.
• Significant cardiac arrhythmias, including QT prolongation.
• Severe hypotension or syncope.
• Elevated prolactin levels leading to galactorrhea or menstrual disturbances.
• Severe depression or suicidal thoughts, particularly in patients with underlying mood disorders.

When prescribing Haloperidol Ratiopharm, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

• Assess patient history for cardiovascular disease, as haloperidol may affect heart rhythm.
• Monitor for signs of extrapyramidal symptoms, especially in elderly patients.
• Use caution in individuals with a history of seizures or other neurologic disorders.
• Evaluate liver and kidney function periodically, since organ impairment can alter drug clearance.
• Consider pregnancy and breastfeeding status; safety data are limited.
• Review any history of neuroleptic malignant syndrome before initiating therapy.
• Avoid abrupt discontinuation to reduce the risk of withdrawal or rebound psychosis.

Haloperidol Ratiopharm may interact with other medications, affecting its efficacy or safety profile.

Avoid

• Concurrent use with other potent dopamine antagonists, which can increase the risk of extrapyramidal side effects.
• Co‑administration with medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Combining with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma concentrations.

Use with caution

• Use with CNS depressants (e.g., benzodiazepines, opioids) as additive sedation may occur.
• Caution when prescribing with anticholinergic agents, which can mask early signs of extrapyramidal symptoms.
• Monitor closely when given with antihypertensive drugs, as haloperidol may enhance hypotensive effects.